NCT01652079View on ClinicalTrials.gov

CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Interventions
DRUG

CRLX101

q 14 days

Trial Locations (4)

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

02215

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01652079 - CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer | Biotech Hunter | Biotech Hunter